SCHEMBL12099625

SCHEMBL12099625

OC1CCN(c2cccc(-n3ccnn3)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 12/20 0.51
▸ KEAP1 Q14145 1/20 0.51
▸ MAPK8 P45983 1/20 0.42
▸ MAPK10 P53779 1/20 0.42
▸ CDK1 P06493 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ HCRTR1 O43613 1/20 0.38
▸ HCRTR2 O43614 1/20 0.38
▸ SLC6A2 P23975 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ LRRK2 Q5S007 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12524335 0.81 NOTUM (0.45) NOTUMKEAP1MAPK8MAPK10HCRTR1
SCHEMBL18726009 0.81 NOTUM (0.55) NOTUMKEAP1MAPK8MAPK10HCRTR1
SCHEMBL29471927 0.79 MAPK8 (0.56) NOTUMKEAP1MAPK8MAPK10MAPT
SCHEMBL14961974 0.79 NOTUM (0.75) NOTUMKEAP1
SCHEMBL12099603 0.76 NOTUM (0.46) NOTUMKEAP1MAPK8MAPK10HCRTR1
SCHEMBL3748592 0.76 MAPK8 (0.78) MAPK8MAPK10
SCHEMBL18726002 0.75 NOTUM (0.53) NOTUMKEAP1MAPK8MAPK10HCRTR1
SCHEMBL19011688 0.75 NOTUM (0.44) NOTUMKEAP1MAPK8MAPK10HCRTR1
SCHEMBL11410355 0.72 NOTUM (0.64) NOTUMKEAP1
SCHEMBL13097313 0.72 MEN1 (0.53) CDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2683687-B1 HETEROCYCLIC DERIVATIVES CONTAINING PRIMARY AMINO GROUPS AND DIAZENIUMDIOLATES MERCK SHARP & DOHME (US) 2017-04-19 — — EP disclosed
EP-2683687-A1 PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES Merck Sharp & Dohme Corp. (US) 2014-01-15 — — EP disclosed
CN-103492366-A Primary amine diazeniumdiolate heterocyclic derivatives MERCK SHARP & DOHME 2014-01-01 — — CN disclosed
US-8361994-B2 Primary amine diazeniumdiolate heterocyclic derivatives MERCK SHARP & DOHME CORP (US) 2013-01-29 — — US disclosed
WO-2012122077-A1 PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2012-09-13 — — WO disclosed
US-20120232039-A1 PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME LLC 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232039-A1 PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES EDNRA, PAH, EDNRB NOTUM 1508/4885KEAP1 217/4885MAPK8 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback